Bibliographic Details
| Title: |
Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors. |
| Authors: |
Swerdloff, Ronald S.1 (AUTHOR) swerdloff@lundquist.org, Bremner, William J.2 (AUTHOR) |
| Source: |
Andrology. Oct2024, Vol. 12 Issue 7, p1547-1550. 4p. |
| Subject Terms: |
*MALE contraceptives, *FAMILY planning, *REPRODUCTIVE rights, *CONTRACEPTIVES, *PHARMACEUTICAL industry |
| Abstract: |
This perspective provides an overview of issues needed to bring a testosterone‐progestogen combined transdermal male hormonal contraceptive to the market. Large‐scale phase 2b trials are near completion and a pivotal trial to confirm efficacy and safety has been designed. We believe we are close to accomplishing the steps necessary to bring the first male‐directed effective, safe, and reversible pharmaceutical contraceptive approach to the public. If successful, we believe it will provide a new option for couples to consider in their family planning. [ABSTRACT FROM AUTHOR] |
|
Copyright of Andrology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
